UK markets closed

argenx SE (0QW0.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
348.10-4.30 (-1.22%)
At close: 05:32PM BST

argenx SE

Laarderhoogtweg 25
Amsterdam 1101EB
Netherlands
31 10 703 8441
https://www.argenx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees843

Key executives

NameTitlePayExercisedYear born
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.CEO & Exec. Director1.44MN/A1972
Mr. Karl GubitzChief Financial OfficerN/AN/A1970
Ms. Malini MoorthyGen. CounselN/AN/A1970
Mr. Arjen Lemmen M.Sc.VP of Corp. Devel. & StrategyN/AN/A1985
Ms. Andria WilkGlobal Head of QualityN/AN/A1974
Mr. Luc TruyenChief Medical OfficerN/AN/A1965
Ms. Karen MasseyChief Operating OfficerN/AN/A1979
Mr. Filip BorgionsVP & Global Head of Technical OperationsN/AN/AN/A
Mr. Peter UlrichtsChief Scientific OfficerN/AN/A1980
Ms. Beth DelGiaccoVP and Global Head of Corp. Communications & Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Corporate governance

argenx SE’s ISS governance QualityScore as of 1 October 2023 is 5. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.